Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
13.52
+0.33 (2.50%)
Jul 17, 2026, 11:43 AM EDT - Market open
Enanta Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Enanta Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $21.17. The average 1-year stock price forecast is 56.58% higher than the current stock price, while the lowest is $19 (+40.53%) and the highest is $28 (+107.10%).
Price Target: $21.17 (+56.58%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Enanta Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 7 | 7 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $20 | Buy | Reiterates | $20 | +47.93% | Jun 23, 2026 |
Unknown Analyst Rodman & Renshaw No rating | Rodman & Renshaw | Buy Initiates $20 | Buy | Initiates | $20 | +47.93% | Mar 26, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $19 | Buy | Maintains | $19 | +40.53% | Mar 3, 2026 |
Financial Forecast
Revenue This Year
66.34M
from 65.32M
Increased by 1.55%
Revenue Next Year
66.57M
from 66.34M
Increased by 0.35%
EPS This Year
-1.88
from -3.84
EPS Next Year
-2.05
from -1.88
EPS and Forward PE are based on non-GAAP adjusted numbers.